Find Clinical Trial

Home » Find Clinical Trials » A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis

← Back

Study Phase	Phase 3

Therapeutic Area	Rheumatology

Indication	Osteoporosis

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	STRONTIUM RANELATE, S012911

Active Substance Code	S012911

Protocol Code	CL3-12911-025

EudraCT Code	2006-005581-39

ISRCTN Code	ISRCTN50493318

Documents and links

Results summary	READ MORE

Scientific publication	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.